RXKINETIX TO MOVE MUCOSITIS DRUG INTO PHASE III

RxKinetix has reported that it will move its investigational drug RK-0202 for the treatment of chemotherapy-induced oral mucositis into Phase III testing.

The company recently completed a Phase II trial of RK-0202 in patients with head and neck cancer. The trial successfully demonstrated the drug's efficacy, with patients receiving RK-0202 having statistically lower incidences of oral mucositis versus placebo.

In addition, significantly fewer patients on RK-0202 required the use of an external feeding tube compared with placebo. Patients receiving RK-0202 also had lower incidence of adverse events such as weight loss, anorexia, dry mouth, nausea and dehydration.